The combination therapy of targeting both paclitaxel and *Dendrophthoe pentandra* leaves extract nanoparticles for improvement breast cancer treatment efficacy by reducing TUBB3 and MAP4 expressions

Sofy Permana¹,², Hilma Lukman², Eviana Norahmawati³, Oktavia Eka Puspita⁴, Dicky Faisal Moh Al Zein², Yoshiyuki Kawamoto⁵ and Agustina Tri Endharti⁶

¹Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Brawijaya, Indonesia; ²Master Program in Biomedical Sciences, Faculty of Medicine, Universitas Brawijaya, Indonesia; ³Department of Pathology Anatomy, Faculty of Medicine, Universitas Brawijaya, Indonesia; ⁴Study Program of Pharmacy, Faculty of Medicine, Universitas Brawijaya, Indonesia; ⁵Bachelor Program of Biology, Faculty of Mathematics and Natural Sciences, Universitas Brawijaya, Indonesia; ⁶Department of Biomedical Sciences, Graduate School of Life and Health Sciences, Chubu University Japan; ⁷Department of Parasitology, Faculty of Medicine, Universitas Brawijaya, Indonesia, Biomedical Central Laboratory, Faculty of Medicine, Universitas Brawijaya, Indonesia

The aim of this study is to investigate the combination treatments of paclitaxel and chitosan-*Dendrophthoe pentandra* leaves extract nanoparticles (NPDP) on MCF-7 breast cancer cells. Chitosan-NPDP nanoparticles were characterized by Fourier-transform infrared (FTIR), scanning electron microscopy (SEM), and assessed by using immunofluorescence microscopy. MCF-7 cells are cultured and divided into six groups: group 1 was a negative control (without paclitaxel or NPDP); group 2 was treated with paclitaxel alone; groups 3-5 were treated with NPDP (2, 4, and 8 mg/mL, respectively) and group 6 was treated only by 8 mg/mL of chitosan-NPDP nanoparticles. The proliferation and cell cycle were analyzed by flow cytometry and the expression of TUBB3 and MAP4 were assessed by immunofluorescence microscopy. The combinations of paclitaxel-NPDP significantly inhibit proliferation of cells (P<0.001) and it is able to induce G2/M cell cycle arrest (P<0.001). The combination of paclitaxel-NPDP significantly decreases the expressions of TUBB3 (P<0.001) and MAP4 (P<0.001) in MCF-7 cells. These results indicate that the combination of NPDP nanoparticles could reduce the expressions of TUBB3 and MAP4. This research may provide possible sources of new therapy for NPDP.

Keywords: cell cycle, *Dendrophthoe pentandra*, MAP4, proliferation, TUBB3

Received: 06 December, 2020; revised: 22 March, 2021; accepted: 04 May, 2021; available on-line: 15 July, 2021

INTRODUCTION

Breast cancer is a common disease in the world and the second leading cause of death from cancer (Abdulkaoreem, 2013). One of the chemotherapy drugs for breast cancer is paclitaxel and it acts as an antimtor by encouraging polymerization and microtubule stabilization (Calaf et al., 2018; Tang et al., 2017). Despite its effectiveness against cancer, paclitaxel has other side effects including fatigue, myalgia, arthralgia, nausea, and neuropenia (Sibaud et al., 2016). Hence, using paclitaxel combined with other medications, to minimize the side effects or to function synergistically, improves paclitaxel’s effects. *Dendrophthoe pentandra*, a mango-growing parasitic plant, has commonly been used as a medicinal plant for treating asthma, measles, cough, skin infections and has been used as a diuretic and an anticancer agent (Arta Challah et al., 2012). *Dendrophthoe pentandra* contains both of kaempferol-3-0-alpha-L-rhamnopyranoside and quercetin-3-0-alpha-L-rhamnopyranoside to prevent colon cancer proliferation (Wiart, 2012; Endharti et al., 2018a). The combination with doxorubicin decreased survivin and iCa²⁺ concentrations (Endharti et al., 2016).

Microtubules were identified as a cancer treatment target to inhibit cell division (Endharti & Permana, 2017). Tubulin βIII (TUBB3) is the most studied microtubule isotype in human cancer. TUBB3 over-expression was linked to poor clinical results in several cancers (Karki & Ferlini, 2014). Microtubule-associated protein 4 (MAP4) was a cytosolic microtubule which plays a significant role in maintaining vascular stability and tumorigenesis (Eduardo et al., 2017; Zhang et al., 2019). Therefore, a drug delivery system which could selectively bring appropriate concentrations of drugs into the targeted cells is needed to increase bioavailability and to reduce the side effects. Nanoparticles may be the therapeutic alternative in this aspect (Cordero et al., 2019; Tang et al., 2017). It is expected that chitosan, an abundant biopolymer as a drug carrier, will evolve and improve the stability, bioavailability, and therapeutic effectiveness of various conditions (Da Silva et al., 2013; Rampino et al., 2013). The efficacy of the combination of nanoparticles chitosan — *Dendrophthoe pentandra* Leaves Extract (NPDP) and paclitaxel as an anti-cancer treatment is still unclear. In this study, we investigated the effects of paclitaxel and chitosan-NPDP nanoparticles combination on TUBB3 and MAP4 in MCF-7 breast cancer cells.
MATERIALS AND METHODS

Plant material and extraction

Fresh leaves of *Dendrophthoe pentandra* have been collected in Probolinggo, East Java, Indonesia and identified at the Department of Biology, Universitas Brawijaya (specimen No. 0170/Taxonomy/Identification/03/2015). The *Dendrophthoe pentandra* leaves were extracted according to Endharti and others (Endharti et al., 2018). Briefly, *Dendrophthoe pentandra* ethanol extract from crushed dried shade leaves was filtered and centrifuged at 5000 rpm for 15 minutes at room-temperature and evaporated at 60±5°C.

Preparation of chitosan-NPDP nanoparticles

The chitosan nanoparticles were prepared with sodium tripolyphosphate (TPP, Sigma-Aldrich, St. Louis, USA) by using the ionic gelation process. Briefly, 2 gram of chitosan (Sigma-Aldrich, USA) was dissolved in 500 ml of 1% acetic acid solution and stirred at 1000 rpm at room temperature for 25 minutes until the solution became clear. The resulting solution was sonicated before being titrated with a pH 5 NaOH solution and filtered through a 0.2 mesh filter. Then, 50g of *Dendrophthoe pentandra* extract (DPE) was added to chitosan-acetic acid solution. Thereafter, in the solution stirring state at room temperature, 2% TPP (w/v) was applied in droplets. By adding the TPP solution to the magnetic stirrer with chitosan solution at 60°C, the resulting nanoparticles and solutions were filtered through a 0.2 mesh filter. Dissolution of 1.2% Tween 80 and 2% acetic acid were used to dissolve Chitosan (0.17–0.18% w/v). For 72 hours the solution was put in a bath sonicator with a magnetic stirrer for 24 hours. Sodium sulphate was then applied and stirred for 1 hour, then sonicated again for 15 minutes. The nano-sized particles were precipitated. Nanoparticles loaded with 100 ml of leaf extract are centrifuged at 5000 rpm for 15 minutes at 4°C. The pellet (6 mg/ml) was taken into normal saline with the 0.5 mg/ml of extract and then resuspended. The suspension was stirred by a magnetic stirrer at 400 rpm for 4 hours and later centrifuged to get loaded nanoparticles.

Imaging-Based Evaluation of chitosan-NPDP

The extracted chitosan-NPDP was characterized by various analytical methods. FT-IR spectra of newly formed chitosan-NPDP nanoparticles were obtained with 64 scans at a resolution of 4.0 cm⁻¹ and the spectrum was recorded at a wavelength of 500–4000 cm⁻¹ (PerkinElmer Spectrum 100 FTIR spectrometer, PerkinElmer Inc., Waltham, MA, USA).

To know the interaction between DPE extract and chitosan, the formation of chitosan-NPDP was further confirmed using the FTIR spectrum. The surface morphology of chitosan-NPDP was studied using a SEM (JSM 7800F, JEOL Ltd., Tokyo, Japan) with a 5 kV accelerating voltage. Using a gold sputtering unit, the test samples (chitosan-NPDP) were placed onto the surface of silicon chips and coated with gold. The operating condition was an accelerated voltage of 5 kV, a pressure of 7 bar and a deposition current of 20 mA.

Cell cultures

The American Type Culture Collection (ATCC) (Bioresearch Centre, Manassas, VA, USA) has obtained human breast cancer cells (MCF-7) cultured in Roswell Park Memorial Institute 1640 medium (RPMI 1640) (Gibco, USA) supplemented with 10% Fetal Bovine Serum (FBS) (Chemical Co., St. Louis, MO, USA), 100 U/ml amphotericin and 100 U/ml penicillin (Gibco, USA). In a 5% CO₂ incubator at 37°C, cells were incubated in humidified air.

Antibodies

The primary antibody used in the research was monoclonal mouse anti-TUBB3 (Santa Cruz Biotechnology, Inc., USA) for βIII tubulin and rabbit anti-MAP4 (Bioscience Inc., USA) for MAP4, while the secondary antibody was conjugated to mouse IgG with fluorescein (Rockland, USA).

The Assessment of Cytotoxicity by MTT Assay

Cytotoxicity by MTT assay was performed using the Endharti protocol (Endharti et al., 2019). Briefly, cells were seeded in the 96-well culture plate at a concentration of 5x10⁴ cells/mL and treated with 0.5–16 μg/mL paclitaxel in single treatment or in combination with NPDP (2, 4 or 8 mg/mL), and then cells were cultured for 24 hours at 37°C in 5% CO₂ and 95% humidity. Next, 100 μL/well of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reagent (MTT, Sigma Chemical Co., St. Louis, MO, USA) was applied to the respective wells at a concentration of 0.5 mg/mL and incubated for 4 hours at 37°C in the CO₂ incubator. Approximately 100 μL of dimethyl sulfoxide (DMSO) was applied to make the formazan easily soluble. ELISA reader was used to assess the optical density (OD) at 630 nm. The percentage inhibition was calculated using the formula: (OD of control − OD of sample/OD of control)×100.

Cell Proliferation Assay

Proliferation assay was performed using Ki67 labeling. Briefly, 1x10⁵ cells were seeded in the 24-well culture plate and treated with 0.5–16 μg/mL paclitaxel in single treatment or in combination with NPDP (2, 4 or 8 mg/mL), and then cells were cultured for 24 hours at 37°C in 5% CO₂ and 95% humidity. Then, cells were harvested and centrifuged for 5 minutes at 200×g. Cells were re-suspended in 200 μl fixation solution and subsequently incubated at room temperature for 20 minutes. Cells were permeabilized in 200 μl (10 mM HEPES) and incubated at room temperature for 20 minutes followed by FITC conjugated-Ki67 (Biosence) incubation at 4°C for 20 minutes in the dark. Cells were washed twice with HBSS containing 5% FBS and 0.1% sodium azide. For DNA staining, cells were stained with (0.5 mg/mL Propidium Iodide (PI, Sigma Chemical Co., St. Louis, MO, USA) at 4°C for 20 minutes. Cells were analyzed after staining using FACS Calibur (Becton Dickinson) flow cytometer and Cell Quest software.

Cell Cycle Analysis

The progression of the cell cycle was assessed by labeling with anti-BrdU conjugated with FITC and staining with Propidium Iodide, according to a method by Endharti and others (Endharti et al., 2016). Briefly, MCF cells were seeded at 1x10⁶ cells per well in 24 well plates and treated with 0.5–16 μg/mL paclitaxel in single treatment or in combination with NPDP (2, 4 or 8 mg/mL), and then cells were cultured for 24 hours at 37°C in 5% CO₂ and 95% humidity. After 24 hours incubation, cells were suspended in cold 70% ethanol for 40 minutes. The cells were then fixed in 70% ethanol for 24 hours at −20°C. The fixed cells were washed twice with PBS and stained with PI (50 μg/mL) for 5 minutes at room temperature. Cells were washed twice with PBS and resuspended in PBS. The sample was then analyzed using FACS Calibur (Becton Dickinson) flow cytometer and Cell Quest software.
were centrifuged and re-suspended in 2 M HCl at 37°C followed by incubation with 0.1 M sodium tetraborate (pH=8.5) for 10 minutes at room temperature. Cells were then permeabilized with 0.1% Tween-20 1% BSA in PBS for 5 minutes at room temperature, followed by the addition of anti-BrdU (Biolegend). For DNA staining, 0.5 mg/ml propidium iodide (PI, Sigma Chemical Co., St. Louis, MO, USA) and 1 mg/ml RNase (Sigma Chemical Co., St. Louis, MO, USA) were incubated for 30 minutes. The cells were eventually assessed using a BD FACS Calibur cytometer (Becton Dickinson, San Jose, CA, USA). The percentage of cells in each phase of the cell cycle was quantitated using Cell Quest Pro software.

Immunofluorescence microscopy

MCF-7 cells were seeded on a glass coverslip on chamber plates and after an overnight incubation cells were treated with NPDP for 48 hours. The glass coverslips were fixed with 4% formaldehyde for 15 minutes, followed by permeabilization with 0.5% Triton X-100 for 15 minutes at room temperature. The cells were blocked with 1% BSA for 1 hour in bovine serum albumin (BSA, Sigma, Chemical Co., St. Louis, MO, USA). Primary antibody was applied overnight at 4°C, followed by incubation with fluorescein conjugated secondary antibody for 1 hour. The nuclei were co-stained with 4',6-diamidino-2-phenylindole (DAPI, Bio Legend, USA) and visualized by using Fluorescence microscopy (OLYMPUS 1X71). Fluorescence quantifications were analyzed by using ImageJ 2 software.

Statistics

Experiments were conducted at least three times. Data were expressed as the mean ± S.D., and normality was tested using the Kolmogorov-Smirnov test. Variables with a non-normal distribution were logarithmically transformed before statistical analysis. The data among multiple groups were analyzed using one-way analysis of variance (ANOVA) followed by post hoc test. Independent significance was defined as a P-value<0.05. All statistical analyses were performed using SPSS 17.0 software.

RESULTS

FTIR characterization of chitosan-NPDP nanoparticles

This study detected the elements and functional groups in the ethanol extract. The Fourier transform infrared (FTIR) spectrum of chitosan-NPDP nanoparticles was shown in (Fig. 1). In chitosan-NPDP nanoparticles spectrum the peak of OH and NH group was at 3200-3600 cm\(^{-1}\). The peak of amide group was seen at 1655 cm\(^{-1}\). The peak of –P=O groups of polyphosphate anion and C-N aliphatic amines were seen at 1273 cm\(^{-1}\) and 1033 cm\(^{-1}\), respectively.

SEM Analysis

The morphology of chitosan- NPDP nanoparticle was observed and shown in (Fig. 2). SEM analysis showed that the particles were nearly spherical in shape.

Cytotoxic activity of paclitaxel- NPDP combined of MCF-7 cell lines

MTT assay was used to assess the effectiveness of paclitaxel-NPDP mediated inhibition of MCF-7 cell production. The cytotoxic activity against MCF-7 cell line was evaluated at different concentrations of NPDP. NPDP nanoparticles have established anticancer activities with or without NPDP. Cell viability was decreased in a dose-dependent manner of each group, when it was compared to the control. The anticancer activity of paclitaxel and NPDP could kill MCF-7 cells by 13%, 29%, and 87%, respectively (Fig. 3).

Paclitaxel-NPDP combined Inhibits Cell Proliferative of MCF-7

In this study, MCF-7 cells proliferation was observed by using Ki67 staining performed by flow cytometer.
MCF-7 cells proliferation was significantly higher in Paclitaxel single group than Paclitaxel-NPDP-combined groups ($P<0.001$) (Fig. 4). It suggests that the combination therapy of Paclitaxel-NPDP suppressed cell viability by reducing the proliferation of MCF-7 cells.

**Paclitaxel-NPDP combination Induces MCF-7 Cells Cycle Arrest in G2/M Phase**

For further studies, the cell cycle distribution after paclitaxel-NPDP conjugation was investigated using a flow cytometer. The data demonstrated that the percentage of cells arrested in G2/M-phase significantly increased in the groups that were treated with paclitaxel-NPDP compared to the untreated one or control ($P<0.001$). These results indicated that paclitaxel-NPDP combination promoted arresting the cell cycle in the G2/M-phase (Fig. 5).

**The combination effect of paclitaxel and NPDP diminish TUBB3 expression**

The expression of TUBB3 was assessed by immunofluorescence microscopy. The data of TUBB3 (Fig. 6a and 6b) confirmed that TUBB3 expression was significantly decreased with paclitaxel and various concentrations of NPDP treatments (2, 4, and 8 mg/mL, respectively). Compared to the control group, the percentage of TUBB3 expression in combination therapy groups decreases by 60% ($P<0.001$).
The expressions of MAP4 were reduced with paclitaxel and NPDP nanoparticles. The harvest cells assessed with BrdU followed by labelling with a FITC conjugated anti-BrdU antibody and Propidium Iodide were analysed as described in Materials and Methods and the percentages of S phase, G0/G1 and G2/M in the areas have been shown. (b) Results are mean values ± S.D. from four independent experiments. *P<0.05, **P<0.001 versus control group.

DISCUSSIONS

The chitosan nanoparticles were prepared by ionic gelation method. NPDP nanoparticles are formed due to the interaction between positive charged chitosan and negative charged TPP (Agarwal et al., 2018). According to the results of FTIR analysis, the 3200–3600 cm⁻¹ peak of OH and NH bonds in chitosan shifted to 2000–2500 cm⁻¹ in NPDP nanoparticles. This result indicated that hydrogen bonding is enhanced due to hydrostatic interaction between amino groups and phosphoric groups in TPP (Agarwal et al., 2018; El Aziz et al., 2018). The 1655 cm⁻¹ peak of amide bending vibrations of chitosan shifted to 1630 cm⁻¹. The shift attributed to interaction between chitosan amide with added polyons of TPP. The observed absorption bands at 1273 cm⁻¹ and 1033 cm⁻¹ have been assigned to −P=O groups of polyphosphate anion and C-N aliphatic amines, respectively (Chandirika et al., 2018; Ibezim et al., 2011).

In this study, we investigated the effects of Paclitaxel and NPDP on the proliferation and cell cycle of MCF-7 cells and its intrinsic mechanism. Previous study proved that Dendropoe pentandra contains quercetin-3-rhamnose, which has anti-cancer effects. Quercetin has potent anti-carcinogenic properties and is known to contribute as a proliferation inhibitor (Endharti et al., 2016). Quercetin also improves the action of 5-Fluourouracil (5-FU) promoting increased apoptosis in breast cancer T47D cells (Endharti et al., 2018b). It was found that Paclitaxel and NPDP have anti-proliferative activity in MCF-7-overexpressing breast cancer cells through cell cycle arrest. Previous studies indicated that flavonoids inhibit cell proliferation via cell cycle at G2/M phase (Zhang et al., 2018; Wei et al., 2019).

This study also showed that after treatment with Paclitaxel-NPDP, the percentage of cells in G2/M phase significantly increased from 36% to 65%. We demonstrated for the first time that NPDP has anti-cancer effects by inducing of G2/M cell cycle arrest and inhibiting cell proliferation. This data indicated that NPDP is
able to induce DNA damage and lead to MCF-7 cells arrest at G2/M phase.

The results of our study showed that the combination of paclitaxel and NPDP nanoparticles decrease the expressions of TUBB3 and MAP4. Although the underlying mechanism is still unclear, the evidence indicates that MAP4 is an important regulator for cancer progression. Du and others (Du et al., 2018) and Gómez-Conde and others (Gómez-Conde et al., 2017) reported that MAP4 plays a role in regulating the migration and proliferation of cancer cells. Quercetin inhibits polymerization of phosphocellulose-purified tubulin into microtubules which have an important role in proliferation. Jiang, et al (2016); Jungwhoi and Jae (Jungwhoi and Jae 2016) reported that TUBB3, which is made up of microtubules, plays a role in cellular processes such as mitosis, proliferation, and cell motility (Person et al., 2017; Sadeghi et al., 2015; Zhenhua et al., 2015; Karki et al., 2014). The TUBB3 expression has a significant cycle-specificity in cell proliferation, of which the expression is increased in the G2-M phase (Endharti et al., 2018; Junhui et al., 2019; Permana et al., 2018; Sadeghi et al., 2015). The effect of paclitaxel and NPDP combination in TUBB3 and MAP4 expressions can be considered as a potential factor in cancer therapy. This finding suggested that the NPDP established mainly anti-effects in three ways: inhibits the growth of MCF-7 cancer cells, inhibits tubulin dimerization on microtubules and causes the arrest of the G2/M cell cycle.

CONCLUSIONS

In conclusion, combination of paclitaxel and NPDP nanoparticles can induce cytotoxicity and is able to reduce TUBB3 and MAP4 expressions in MCF-7 breast cancer. This finding may be a promising method for a new concept of anti-cancer therapy, especially in the treatment of breast cancer.

Conflicts of Interest

The authors declare that they have no conflict of interests.

REFERENCES


Figure 7. The combination therapy of NPDP with paclitaxel reduced the expressions of MAP4 in MCF-7 cells.

(a) MCF-7 cells were treated with paclitaxel single or combinations with NPDP 2, 4, and 8 mg/mL, respectively. Red arrow: MAP4 positive cell. All images were magnified in representative four independent experiments. *P<0.05 **P<0.001 versus control group.


Sadeghi I, Behmanesh M, Ahmadian Chashmi N, Sharifi M, Soltani BM (2015) 6-methoxy podophyllotoxin induces apoptosis via inhibi-


